title: Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
abstract: Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.
authors.affiliation: Dipartimento di Biotecnologie Umane ed Ematologia, Università "La Sapienza" di Roma, Via Benevento 6-00161, Rome, Italy. rob.lati@libero.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Latagliata
authors.forename: Latagliata
authors.initials: L
authors.lastname: Roberto
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Breccia
authors.initials: B
authors.lastname: Massimo
authors.forename: Ida
authors.initials: I
authors.lastname: Carmosino
authors.forename: Carmosino
authors.initials: C
authors.lastname: Ida
authors.forename: Chiara
authors.initials: C
authors.lastname: Sarlo
authors.forename: Sarlo
authors.initials: S
authors.lastname: Chiara
authors.forename: Enrico
authors.initials: E
authors.lastname: Montefusco
authors.forename: Montefusco
authors.initials: M
authors.lastname: Enrico
authors.forename: Marco
authors.initials: M
authors.lastname: Mancini
authors.forename: Mancini
authors.initials: M
authors.lastname: Marco
authors.forename: Fiammetta
authors.initials: F
authors.lastname: Natalino
authors.forename: Natalino
authors.initials: N
authors.lastname: Fiammetta
authors.forename: Antonio
authors.initials: A
authors.lastname: Chistolini
authors.forename: Chistolini
authors.initials: C
authors.lastname: Antonio
authors.forename: Rosa
authors.initials: R
authors.lastname: De Cuia
authors.forename: De Cuia
authors.initials: de C
authors.lastname: Rosa
authors.forename: Eleonora
authors.initials: E
authors.lastname: Russo
authors.forename: Russo
authors.initials: R
authors.lastname: Eleonora
authors.forename: Giacomo Salvatore
authors.initials: GS
authors.lastname: Morano
authors.forename: Morano Salvatore
authors.initials: MS
authors.lastname: Giacomo
authors.forename: Francesca
authors.initials: F
authors.lastname: Biondo
authors.forename: Biondo
authors.initials: B
authors.lastname: Francesca
authors.forename: Antonio
authors.initials: A
authors.lastname: Spadea
authors.forename: Spadea
authors.initials: S
authors.lastname: Antonio
authors.forename: Franco
authors.initials: F
authors.lastname: Mandelli
authors.forename: Mandelli
authors.initials: M
authors.lastname: Franco
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Alimena
authors.initials: A
authors.lastname: Giuliana
mesh_terms: D000367:Age Factors; D000368:Aged; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate